Volume 139, Issue 4, Pages 1207-1217.e3 (October 2010) Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection  Thomas Berg, Patrick Marcellin, Fabien Zoulim, Bernd Moller, Huy Trinh, Sing Chan, Emilio Suarez, Fabien Lavocat, Andrea Snow– Lampart, David Frederick, Jeff Sorbel, Katyna Borroto–Esoda, David Oldach, Franck Rousseau  Gastroenterology  Volume 139, Issue 4, Pages 1207-1217.e3 (October 2010) DOI: 10.1053/j.gastro.2010.06.053 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 Mean (95% confidence interval) HBV DNA (log10 copies/mL) by study visit (RAT analysis set) and initial treatment assignment. Gastroenterology 2010 139, 1207-1217.e3DOI: (10.1053/j.gastro.2010.06.053) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 Percentage of patients with HBV DNA <400 copies/mL by study visit and initial treatment assignment (intent-to-treat: NC = F analysis). Patients who switched to open-label FTC/TDF after week 24 were included in the analysis as part of their original randomized treatment group. Gastroenterology 2010 139, 1207-1217.e3DOI: (10.1053/j.gastro.2010.06.053) Copyright © 2010 AGA Institute Terms and Conditions

Figure 3 (A and B) Median change in HBV DNA by baseline ADV-R (A) or LAM-R (B) detected by population sequencing. Gastroenterology 2010 139, 1207-1217.e3DOI: (10.1053/j.gastro.2010.06.053) Copyright © 2010 AGA Institute Terms and Conditions

Figure 4 (A and B) Median change in HBV DNA by baseline ADV-R (A) or LAM-R (B) detected by INNO-LiPA. Gastroenterology 2010 139, 1207-1217.e3DOI: (10.1053/j.gastro.2010.06.053) Copyright © 2010 AGA Institute Terms and Conditions

Supplementary Figure 1 Disposition of study patients. Gastroenterology 2010 139, 1207-1217.e3DOI: (10.1053/j.gastro.2010.06.053) Copyright © 2010 AGA Institute Terms and Conditions

Supplementary Figure 2 HBV DNA log10 copies/mL by study visit for patients randomized to blinded tenofovir disoproxil fumarate treatment who switched to open-label emtricitabine/tenofovir disoproxil fumarate treatment after week 24. Gastroenterology 2010 139, 1207-1217.e3DOI: (10.1053/j.gastro.2010.06.053) Copyright © 2010 AGA Institute Terms and Conditions

Supplementary Figure 3 Percentage of patients with HBV DNA <400 copies/mL by adherence. High adherence was defined as ≥94%, and low adherence was defined as ≤68%. Patient adherence to study drug was measured by a count of pills returned at each postbaseline visit. Gastroenterology 2010 139, 1207-1217.e3DOI: (10.1053/j.gastro.2010.06.053) Copyright © 2010 AGA Institute Terms and Conditions